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PEMBANGUNAN DAN PENILAIAN PELBAGAI GEN MUTAN 
VIBRIO CHOLERAE O139 SEBAGAI CALON VAKSIN  
ABSTRAK 
Kolera merupakan isu kesihatan yang memberi kesan ke atas jutaan nyawa setiap 
tahun. Berdasarkan wabak penyakit kolera yang sentiasa berulang, penghasilan vaksin yang 
membolehkan pengvaksinan dilakukan secara meluas adalah amat perlu. Dalam kajian ini, 
calon vaksin yang diubahsuai secara genetik, VCUSM21P dan VCUSM22P telah dihasilkan. 
VCUSM21P merupakan vaksin prototrof yang mengkodkan „cholera toxin A‟ (ctxA) tidak 
bertoksik dan mempunyai mutasi pada gen-gen „accessory cholera enterotoxin (ace)‟, 
„zonula occludens toxin (zot)‟ dan „repeats-in-toxin C/A (rtxC/A)‟. Manakala calon vaksin 
VCUSM22P mempunyai mutasi pada ace, zot, ctxA, rtxC/A dan „haemagglutinin/protease 
(hap)‟. Kedua-dua mutan ini didapati tidak menjejaskan penyusunan aktin pada sel-sel 
HEp2. Kajian kolonisasi dalam usus mencit („infant mouse‟) digunakan bagi menentukan 
kebolehan VCUSM21P dan VCUSM22P mengkoloni secara in vivo. Kajian usus arnab 
(„rabbit ileal loop‟) dilakukan untuk menilai reaktogenisiti yang disebabkan oleh kedua-dua 
strain mutan tersebut. Gerak balas imunisasi dijana oleh mutan serta kerintangan terhadap 
kolera telah dinilai melalui model arnab. Kedua-dua calon mutan didapati mengkoloni usus 
mencit dengan baik. Dalam kajian model usus menggunakan arnab yang tidak diimunisasi, 
cecair didapati berkumpul dalam gelungan usus yang disuntik dengan „Wild Type‟ (WT) V. 
cholerae pada konsentrasi 1x10
6
 and 1x10
8
 unit formasi koloni „colony forming unit (CFU)‟. 
Sebaliknya, gelungan usus yang disuntik dengan kedua-dua strain mutan pada konsentrasi 
yang sama didapati tidak menyebabkan sebarang reaktogenisiti pada arnab yang tidak imun. 
Imunisasi menggunakan strain kedua-dua mutan pada konsentrasi 1x10
10
 CFU telah 
meningkatkan penghasilan antibodi IgA dan IgG terhadap toksin kolera dan lipopolisakarida 
(LPS) O139 serta meningkatkan antibodi „vibriocidal‟. Reaktogenisiti yang disebabkan oleh 
WT V. cholerae pada arnab yang telah diimun dengan 1x10
10
 CFU strain-strain mutan 
xxi 
 
didapati berkurangan berdasarkan ketiadaan cecair terkumpul dalam gelung usus arnab yang 
disuntik dengan WT V. cholerae pada konsentrasi 1x10
2
 - 1x10
7
 CFU. Kajian cirit-birit pada 
model usus arnab dewasa „Removable Intestinal Tie Adult Rabbit Diarrhoea (RITARD)‟ 
mendapati arnab yang tidak diimun tidak dilingungi terhadap infeksi WT V. cholerae pada 
dos 1x10
9
 CFU. Walaubagaimanapun, 100% arnab yang telah diimun didapati rintang 
terhadap WT V. cholerae. Pemeriksaan secara imunohistokimia, histopatologi dan 
ultrastruktur pada usus arnab yang tidak diimun dan telah diinfeksi dengan WT V. cholerae 
menunjukkan kerosakan yang teruk berlaku pada usus kecil. Sebaliknya, tiada kerosakan 
berlaku pada bahagian tersebut apabila arnab yang telah diimun diuji dengan WT V. 
cholerae. Strain VCUSM21P dan VCUSM22P boleh digunakan dalam vaksinasi terhadap 
kolera yang disebabkan oleh V. cholerae O139. 
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CONSTRUCTION AND EVALUATION OF MULTIGENE 
MUTANTS OF VIBRIO CHOLERAE O139 AS VACCINE 
CANDIDATES  
ABSTRACT 
Cholera is a major health issue, affecting millions of lives annually. In light of the 
recurrent outbreaks of cholera, there is a pressing need for the development of vaccines that 
allow rapid mass vaccination. In this study, genetically modified vaccine candidates, 
VCUSM21P and VCUSM22P, were designed. VCUSM21P is a prototrophic vaccine which 
encodes non-toxic cholera toxin A (ctxA) subunit immunogen and has accessory cholera 
enterotoxin (ace), zonula occludens toxin (zot) and repeats-in-toxin C/A (rtxC/A) mutations. 
On the other hand, VCUSM22P is ace, zot, ctxA, rtxC/A and haemagglutinin/protease (hap) 
mutant. Both mutants were found not to disassemble the actin of HEp2 cells. Mouse 
colonization assay was used to determine VCUSM21P and VCUSM22P colonization ability 
in vivo. Rabbit ileal loop assay was performed to evaluate the reactogenicity caused by them. 
The immune responses provoked by the two vaccine candidates and their protective function 
against cholera were evaluated in a rabbit model. The mutants were found to be good 
colonizer of the mouse intestine. In the ileal loop assay using non-immunized rabbits, fluid 
accumulation was found in loops injected with 1x10
6
 and 1x10
8
 colony forming unit (CFU) 
of Wild Type (WT) V. cholerae. Unlike the WT V. cholerae challenge, 1x10
6
 and 1x10
8
 
colony forming unit (CFU) of the mutants did not cause any reactogenicity in non-
immunized rabbits. Immunization using 1x10
10
 CFU of the mutants induced both IgA and 
IgG antibodies production against cholera toxin (CT) and O139 lipopolysaccharides (LPS), 
as well as elevated vibriocidal antibody. The reactogenicity caused by the WT V. cholerae in 
rabbits immunized with 1x10
10
 CFU of the mutants was found to be reduced as evidenced by 
absence of fluid in loops administered with 1x10
2
-1x10
7
 CFU of WT V. cholerae. In the 
Removable Intestinal Tie Adult Rabbit Diarrhoea (RITARD) experiment, the non-
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immunized rabbits were found unprotected against a lethal challenge with 1x10
9
 CFU WT V. 
cholerae. However, 100% of rabbits immunized with the mutants survived the WT V. 
cholerae challenge. Immunohistochemical, histopathological and ultrastructural examination 
of non-immunized rabbits‟ ileum challenged with WT V. cholerae revealed severe ileal 
damages. But less severe damages were noted following the WT V. cholerae challenge in the 
ileum of rabbits immunized with VCUSM21P and VCUSM22P. The multigene mutants 
could be used for vaccination against potentially fatal V. cholerae O139.  
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CHAPTER 1 – INTRODUCTION 
 
1.1 Vibrio cholerae and cholera 
Cholera is the most feared disease in history (Seas and Gotuzzo, 1996).  The 
hallmark of cholera is a profuse secretory diarrhoea, with an output rate of as much as 1 liter 
per hour (Phillips, 1966). Thus, cholera is known as an acute secretory diarrhoeal disease. 
This highly liquid diarrhoea, colloquially referred to as “rice-water stool” as it looks like 
water with flecks of rice in it, is loaded with bacteria and has a "fishy" odor (Gorbach et al., 
1970; Kaper et al., 1995).  
Vibrio cholerae (also referred to as Kommabacillus) is a non-invasive Gram-
negative comma shaped bacteria with a single polar flagellum (Heidelberg et al., 2000). It 
belongs to the γ subdivision of the family Proteobacteriaceae. The V. cholerae species 
encompasses more than 200 serogroups (Chatterjee and Chaudhuri, 2003). Among these
 
serogroups, only two toxigenic
 
strains of V. cholerae O1 and O139 were identified to cause 
cholera and are associated with epidemic and pandemic forms of the disease (Chatterjee and 
Chaudhuri, 2003). The principal virulence
 
factor of V. cholerae is cholera toxin (CT) (Kaper 
and Srivastava, 1992; Kaper et al., 1995). 
Cholera can influence negatively to a country‟s economy (Seas and Gotuzzo, 1996; 
Cash and Narasimhan, 2000; Kirigia et al., 2009) and is one of those diseases that can brand 
a country as backwards (Dajer, 1992). The disease is perceived to be a highly contagious 
threat that can spread through international trade in food (WHO, 1993). 
1.2 Prevalence of cholera 
According to the World Health Organization (WHO), the intestinal disease cholera 
poses serious health risks in developing countries, notably in the most underprivileged 
regions of the world (WHO, 2005). Sporadic outbreaks and epidemics occur when large 
populations are displaced following natural disasters or political crisis  and conflict in war 
zones, where there is disturbed living conditions, no clean water or adequate sewage disposal 
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(Siddique et al., 1989; Gabastou et al., 2002; Chaignat et al., 2008; Ekra et al., 2009; Ganin, 
2009; Bhunia and Ghosh, 2011). Cholera had a tragic impact on the personal as well as 
social life of people living in endemic areas (Ghose, 2011). 
The true burden of cholera disease is grossly underestimated as more than 90% of 
the cases went unreported to WHO (Sanchez and Holmgren, 2005). Every year, more than 
100,000 cholera cases and 2,000-3,000 deaths are officially reported to WHO (Fournier and 
Quilici, 2007). In 2006 alone, 52 countries officially reported a total of 236,896 cholera 
cases including 6,311 deaths to the WHO (WHO, 2007). Table 1.1 shows the global update 
reports on a number of verified cholera outbreaks in 2009. Cholera is endemic in the East 
Africa corridor, large estuarine deltas in Asia (Ganges, Mekong) and countries in Northwest 
Africa (Lopez et al., 2008). Imported cases of cholera are reported sporadically around the 
world from travellers to endemic countries (WHO, 1995; Steffen et al., 2003; Tarantola et 
al., 2005; Ajzenman et al., 2006).  
According to WHO, despite efforts taken at country level there has been no 
concrete global improvement to limit transmission rate (Chaignat and Monti, 2007). This 
disease has been rare in industrialized nations but remains as a major public health problem 
in the developing countries, particularly in low-income countries (Kaper et al., 1995; 
Chaignat and Monti, 2007; Lopez et al., 2008; Talavera and Perez, 2009). In endemic areas, 
children are affected the most (Deen et al., 2008). Notification of cholera is compulsory, yet 
countries are reluctant to report cases or seek support from WHO due to fear of possible 
commercial sanction (Chaignat and Monti, 2007; WHO, 2007). Because of the lack of data 
on trends and patterns of cholera outbreaks, predicting potential outbreaks could not be 
possibly achieved (Chaignat and Monti, 2007). 
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Table 1.1: Global update reports on a number of verified cholera outbreaks in 2009* 
 
Country Report References 
Africa 
 
Angola 
 
Since January 2009, 1,250 cases with 35 deaths have been reported countrywide.  As of 
the week of 12 July 2009 15 new cases, with no deaths had been reported from the 
provinces of Bengo, Benguela, Huila, and Malange. 
(NaTHNaC, 2009) 
 DR Congo 
 
As of 20 July 2009, 4,326 cases with 63 d eaths have been reported in South Kivu, and 
2,342 cases with 27 deaths in North Kivu. 
(NaTHNaC, 2009) 
 Kenya 
 
As of 20 July 2009, 4,269 suspected cases with 94 deaths have been reported from 32 
districts countrywide.  
(NaTHNaC, 2009) 
 Malawi 
 
Between 15 November 2008 and 20 July 2009, 5,269 cases were reported. The most 
recent reports of new cases were during the period of 18 to 24 May, with 17 cases 
reported from Machinga district. 
(NaTHNaC, 2009) 
 Mozambique As of 16 May 2009, 17,761 cases with 140 deaths were reported from 54 districts. (NaTHNaC, 2009) 
 South Africa As of 1 June 2009, 12,752 cases with 65 deaths have been reported. Cases were from all 
9 provinces with most cases from Limpopo (5,520), Mpumalanga (6,855), and Gauteng 
(286).  
(NaTHNaC, 2009) 
 Zambia Between 10 September 2008 and 7 May 2009, the cumulative number of cases reported 
was 8,219 with 173 deaths.  
(NaTHNaC, 2009) 
* This is not a comprehensive listing 
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Table 1.1: Continued 
 
Country Report References 
Africa 
 
Zimbabwe 
 
The cholera outbreak that started in August 2008 continues to diminish. Since 13 June 
2009, only one case has been reported (UMP district), bringing the cumulative number of 
cases to 98,592 with 4,288 deaths.  
(NaTHNaC, 2009) 
Europe Swaziland  
 
Between December 2008 and 1 June 2009, 17,448 cases of Acute Watery Diarrhoea 
(AWD) were reported. Two of the AWD cases have been confirmed as cholera. 
(NaTHNaC, 2009) 
South 
Asia 
 
Nepal 
 
As of 30 July 2009, there have been 27,456 cases of diarrhoeal illness in the remote 
Jajarkot district, with 197 deaths. The infection has spread to adjoining districts including 
Rukum, Salyan, Surkhet, Rolpa, Dailekh, and Dang (mid-western region), and to Bajura 
and Dadeldhura (far-west region). This outbreak of diarrhoea is being treated as cholera 
following the isolation of V. cholerae in some samples examined by the National Public 
Health Laboratory of Nepal. 
(NaTHNaC, 2009) 
South East 
Asia 
Malaysia In Nov 2009, a total of 98 people from state of Terengganu were suspected of having 
cholera after showing symptoms like vomiting and acute diarrhoea, with 11 patients being 
tested positive. 187 cases were reported since the outbreak started on Nov 11. 
(BERNAMA, 2009; 
thestar, 2010) 
Europe Swaziland  
 
Between December 2008 and 1 June 2009, 17,448 cases of Acute Watery Diarrhoea 
(AWD) were reported. Two of the AWD cases have been confirmed as cholera. 
(NaTHNaC, 2009) 
* This is not a comprehensive listing 
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1.3 Discovery and Historical Background of V. cholerae 
In 1854, the Italian physician Filippo Pacini (1812 to 1883), professor of anatomy 
at the University of Florence,
 
first discovered V. cholerae (Bentivoglio and Pacini, 1995). 
Records of a cholera-like disease have already been mentioned in ancient Sanskrit writings 
on the Indian subcontinent roughly 2,500 years ago (Colwell, 1996) and at the times of 
Hippocrates, 460 to 377 BC (Thompson et al., 2004). Before Pacini‟s discovery, scientists 
and physicians widely believed in
 
the miasmatic theory of disease, a theory of disease 
causation
 
by miasma (ancient Greek: "pollution"), a noxious form of "bad air" or pestilential 
airs (Thompson et al., 2004). Pacini pointed out that cholera was a contagious disease caused 
by V. cholerae, a conclusion he drew after examining the intestinal mucosa of victims of 
cholera (Bentivoglio and Pacini, 1995).  
In the same period, John Snow
 
(1813 to 1858), a doctor known as the father of 
epidemiology, studied cholera (Hare, 1955).  Snow studied the epidemiology of cholera in 
several
 
cities of England (Cameron and Jones, 1983). Between
 
the 1830s and 1850s, and 
during the London cholera epidemic of 1854, cholera had killed tens of thousands of people 
in England (Hare, 1955). According to Snow, cholera was not passed by bad air (Thompson 
et al., 2004). He felt that the outbreak that occurred in the Soho District of London and in 
and around Broad Street was due to contaminated water. Looking in his microscope, Snow 
found the water from a water pump located on Broad Street contained bacteria which he had 
not seen before and concluded them as "morbid poison entering the alimentary canal" 
(Thompson et al., 2004). Snow‟s theory worked when the epidemic began to subside a short 
time after the neighbourhood's source of contaminated water was blocked by removing the 
pump handle (Bentivoglio and Pacini, 1995; Buechner et al., 2004).  
Nearly 30 years later, Robert Koch characterized V. cholerae as comma shaped, 
highly
 
motile and concluded that it was indeed the causative agent of cholera (Thompson et 
al., 2004). He realized that many V. cholerae strains were non-pathogenic
 
for humans. Koch 
found that these vibrios were ubiquitous in aquatic
 
settings and proposed that
 
filtration of 
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drinking
 
water should be incorporated to remove the bacteria from water supply systems 
(Thompson et al., 2004).  
1.4 Classification 
The primary basis of classification of strains of V. cholerae is a serotyping scheme, 
which depends on the properties
 
of somatic (O) antigen. V. cholerae O1 is classified into two 
biotypes, namely „classical‟ and „El Tor‟. Each biotype is further sub-classified into three 
serotypes, called Inaba, Ogawa and Hikojima (is very rare) based on agglutination in 
antiserum. The antigenic determinants of Ogawa are type A and B antigens, determinants of 
Inaba are type A and C antigens, and A, B and C antigens for Hikojima.  Strains other than 
O1 are called non-O1 (Nair et al., 1994b). 
1.5 Cholera Pandemic  
Since 1817, seven cholera pandemics have spread to the world (Faruque et al., 
1998; Boutin et al., 2001). It is believed that the first six of these pandemics were caused by 
the ancient infectious classical
 
biotype originated
 
from the Gangetic delta of Bengal (Sanyal, 
2000). The dominant cause of cholera epidemic by the classical biotype until 1961 were
 
replaced by El Tor strains (Faruque et al., 1998; Sack et al., 2004). The seventh was caused 
by the El Tor biotype (Faruque et al., 1998). The seventh
 
pandemic started from the Sulawesi 
Island and is still ongoing (Kaper et al., 1995; Faruque et al., 1998). V. cholerae serotype O1 
El Tor N16961 strain harbouring the classical CTX prophage (CTXφ) had caused the most 
cholera pandemic (Faruque et al., 1998).  
In late 1992, V. cholerae serogroup O139 appeared in India (Albert et al., 1993; 
Ramamurthy et al., 1993). It spread rapidly to Bangladesh and other Asian countries, thus 
appears to be confined to Asia (Sack et al., 1996; WHO, 2008). V. cholerae O139 is believed 
to be derived from and closely related to O1 El Tor strain (Berche et al., 1994; Jiang et al., 
2000). How O139 serogroup established successful pandemics and overtook  its predecessor 
remains a mystery (MMWR, 1993; Nair et al., 1994a; Siddique et al., 1996). Uniquely, V. 
cholerae serogroup O139 does have a polysaccharide capsule which is not found in its 
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predecessor V. cholerae O1 strain. The capsule is made up of N-acetylglucosamine, N-
acetylquinovosamine (QuiNAc), galacturonic acid (GalA), galactose, and two residues of 
3,6-dideoxyxylohexose (Xylhex) (Preston et al., 1995).  
1.6 Epidemiology of Cholera  
The burden of cholera is predominantly borne by the developing countries of 
Africa and Asia (Miller et al., 1985; Griffith et al., 2006). Usually, V. cholerae is transmitted 
through the faeces of an infected person, due to poor sanitation practice and inadequate 
sanitary facilities (Misch, 1991; Seas and Gotuzzo, 1996). Highly contagious form of the 
disease happens in densely populated and economically reduced areas (Oeding, 1990; Misch, 
1991; Dajer, 1992;  Falade and Lawoyin, 1999). Foodborne transmission of cholera has been 
well documented by epidemiologic investigations in nearly every continent (Estrada-Garcia 
and Mintz, 1996), mainly due to consuming raw or partially cooked seafood such as fish, 
shellfish, crabs, oysters and clams (Dutt et al., 1971; Goh and Lam, 1981; Desenclos, 1996; 
Eberhart-Phillips et al., 1996; Rabbani and Greenough, 1999; Morris, 2003). 
An individual's susceptibility to cholera is affected by one‟s  blood group (Glass et 
al., 1985; Anstee, 2010). Individuals with group AB are the most resistant to cholera disease 
and group A being more resistant than group B. Individuals with the most severe diarrhoea 
compared with those with asymptomatic infection were more often of blood group O and 
less often of AB, indicating that those with group O blood are the most susceptible (Glass et 
al., 1985). In individuals with a weakened immune system or decreased gastric acidity or 
those who are malnourished, increased susceptibility to disease may be observed. 
Worldwide there has been an increase in the number of cholera cases and outbreaks 
with changing profiles (WHO, 2007). Cholera cases are being reported from novel 
communities or in communities where the disease has been absent for many years (WHO, 
2007). This has signified that the geographical distribution of cholera is changing (WHO, 
2007), The reason for the changes is not known but has been associated with the  weather 
conditions that were favourable for transmission.  
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Cholera is a climate-related infectious disease (Islam et al., 2009; Paz, 2009; 
Hashizume et al., 2010). Epidemiologic research suggests that the changes in the 
environment or climate  and the El Nino phenomenon has made conditions favourable for 
cholera worldwide (Lipp et al., 2002; Constantin de Magny and Colwell, 2009). The term El 
Niño is used to refer to the periods of strong and prolonged warm weather. It influences the 
climate worldwide and brings natural disasters such as storms, floods and droughts and 
famine in far-flung parts of the world. The periods of the warm waters in eastern Pacific (El 
Niño) and periods of cooler waters (La Niña) are accompanied by changes of air pressure in 
the east and west Pacific. The whole cycle is now referred to as El Niño Southern Oscillation 
(ENSO) (WHO, 1998). Cholera dynamics is influenced by climate, and in endemic regions 
cholera display regular seasonal cycles and pronounced interannual variability  (Pascual et 
al., 2002). 
Few evidences are now showing that in an epidemic, cholera outbreaks are 
connected to climate change and immunity level in a population (Koelle et al., 2005; King et 
al., 2008). Koelle and colleagues presented a study based on climate force and temporary 
immunity to explain the role of climate variability in interannual disease cycles present in a 
four-decade cholera time series from Matlab, Bangladesh (Koelle, 2009). They used a 
nonlinear population model that takes into account immunity and disease transmission to 
show a strong correspondence between cholera transmission and climate variability, 
expanding the view of the pivotal climatological and immunological influences in cholera 
transmission. By analyzing the temporal variability of the predominant strain, El Tor, the 
authors showed that cholera transmission was promoted when the host population had low 
levels of naturally acquired immunity to reinfection with cholera of the El Tor biotype, 
especially when they were not in a refractory period from previous disease outbreaks. They 
also discovered that high transmission rates fell most heavily when both floods and droughts 
occurred.  
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1.7 Genome structure 
The genome of V. cholerae El Tor N16961 strain was mapped by the team at The 
Institute for Genomic Research (TIGR) in Rockville, Maryland, which completed the 
sequencing using the shotgun procedure (Heidelberg et al., 2000). V. cholerae chromosome 
consists of two unique and circular replicons. The larger first chromosome, chromosome 1, 
has 2,961,149 base pairs and chromosome 2 has 1,072,315 base pairs. Together the 
chromosomes encode 3,885 open reading frames (ORFs), the first has 2,770 ORFs and 
second has 1,115 ORFs (Heidelberg et al., 2000).   
Unlike the smaller second chromosome, chromosome 1 contains the crucial genes 
for toxicity (for example, toxins, surface antigens and adhesins), regulation of toxicity and 
important cellular functions, such as DNA replication, transcription, translation and cell-wall 
biosynthesis. The genes required to produce cholera toxin (CT) are located on it (Heidelberg 
et al., 2000). 
Chromosome 2 contains many more genes that appear to have origins other than 
the gamma-Proteobacteria. The second chromosome may have originally been a 
megaplasmid that was captured by an ancestral Vibrio species. This chromosome gives the 
organism a more competitive advantage in diverse environments. The authors suggest that 
gene exchange between chromosome 1 and 2 occurred over evolutionary time and both 
chromosomes became crucial for the organism to survive (Heidelberg et al., 2000).  
1.8 Horizontal gene transfer 
The ability of the O1 and O139 biotypes to produce CT appears to be the result of 
horizontal gene transfer. The DNA that codes for CT is thought to be the genome of a 
filamentous bacteriophage (CTXφ) that lysogenizes V. cholerae (Lipp et al., 2002). The 
CTXφ genome also includes genes required for virion assembly and secretion, replication 
(rstA), regulation of phage gene expression (rstR) and phage integration (rstB) (Davis and 
Waldor, 2003). It is unclear what role rstB plays in CTXφ integration (Sarah and Matthew, 
2004). The CTXφ genome also contains two intergenic regions, ig-1 and ig-2. The former, 
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lies between ctxB and rstR, contains the phage origin of replication and the sequences 
required for chromosomal integration. The latter contains the transcriptional regulatory 
regions for rstA and rstR (Kimsey and Waldor, 2004). 
CTXφ integrates site-specifically into the larger of the two V. cholerae 
chromosomes (Pearson et al., 1993; Huber and Waldor, 2002), converting non-pathogenic 
isolates of V. cholerae to toxigenic strain (Waldor and Mekalanos, 1996). Its integration 
depends on the chromosome-encoded tyrosine recombinases XerC and XerD of V. cholerae, 
as its genome lacks an integrase. During integration, recombination occurs between regions 
of homology in CTXφ genome (attP) and the V. cholerae chromosome (attB) (Sarah and 
Matthew, 2004).  
1.9 Ecology 
Water connects humans with V. cholerae (Reidl and Klose, 2002). V. cholerae 
thrives in water ecology and finds favourable conditions in waters characterized by moderate 
salinity, high nutrient content, warm temperature, neutral or slightly alkaline pH (Borroto, 
1997). They are highly abundant in aquatic environments and are virtually always detected in 
tropical environments (Shears, 1994). They are found in estuaries, marine coastal waters and 
sediments, and aquaculture
 
settings worldwide (Khan et al., 1984; Borroto, 1997; Faruque et 
al., 1998; Hervio-Heath et al., 2002; Vezzulli et al., 2009). They are a commensal of 
abalones,
 
bivalves, copepods, corals, fish, molluscs, seagrass, sponges, shrimp, seaweed and 
zooplankton (Borroto, 1997; Faruque et al., 1998; Gallardo et al., 2004; Thompson et al., 
2004; Gopal et al., 2005; Aguirre-Macedo et al., 2008). Cholera outbreaks are linked
 
with 
algae and planktonic blooms and the sea surface temperature ( Epstein, 1993; Lobitz et al., 
2000). It is thought that seasonal outbreaks are triggered by seasonal blooming of aquatic 
planktons (Epstein, 1993). This is why in endemic regions, such as South Asia, cholera is 
seasonal. Thus, potential outbreaks may be predicted by monitoring these parameters
 
by 
remote sensing (Lobitz et al., 2000). 
The bacterium enters a quiescent state in water ecology known as viable but non-
culturable (VBNC) state, where it is alive but fails to multiply unless triggered by specific 
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environmental conditions (Colwell and Huq, 1994). They are identified as VBNC form of V. 
cholerae in a wide range of  marine life, including cyanobacteria (Anabaena variabilis), 
diatoms (Skeletonema costatum), phaeophytes (Ascophyllum nodosum), in copepod molts, 
and in freshwater vascular aquatic plants (water hyacinths and duckweed) (Epstein, 1993). 
In nature, V. cholerae grows as matrix-enclosed surface-associated communities 
known as biofilms that are critical for the environmental survival and transmission of V. 
cholerae (Thompson et al., 2004). In biofilms, V. cholerae can resist antibiotics, and 
establish favourable partnerships
 
with other bacteria or hosts. Biofilms also help them in 
trapping and absorbing nutrients. Biofilm formation is linked to the predominant cause of 
cholera as the strong ability of
 
V. cholerae to form densely packed biofilms in the 
environment
 
gives a survival advantage to this organism (Thompson et al., 2004). 
1.10 Antibiotic Resistance 
The Centers for Disease Control and Prevention (CDC) has pointed out an increase 
in the incidence of antibiotic resistant strains of V. cholerae, resulting in further challenges 
for the antimicrobial therapy of cholera (Mahon et al., 1996). Some cholera outbreaks show 
sporadic cases of antibiotic resistance (Kitaoka et al., 2011; Taneja et al., 2011). V. cholerae 
resistance to antimicrobials is due to the injudicious use of antimicrobials. Therefore, 
changes in current methods of prevention and treatment using antimicrobials should be 
considered ( Weber et al., 1994; Ghosh and Ramamurthy, 2011).  
1.11 Pathophysiology of cholera 
After oral ingestion of contaminated food or water, the comma shaped vibrios lead 
their way to the acid rich stomach. As much as 10
8
 CFU of inoculum doses can be infective 
and cause the disease symptoms (Sack et al., 2004). The bacteria that have overcome the 
normal defences of acidic stomach infect the intestine by penetrating the mucus layer and 
colonizing the small intestinal mucosa. Specific adherence of V. cholerae to the intestinal 
mucosa is mediated by toxin coregulated pilus (Tcp), a long filamentous fimbriae that form 
bundles at the poles of the cells. These fimbriae have been termed as Tcp because expression 
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of these pili genes is coregulated with expression of the CT genes. For its adherence to the 
intestinal mucosa, V. cholerae might also use nonfimbrial adhesins to mediate a tighter 
binding to host cells than is attainable with fimbriae alone (Ghose, 1996). Other colonization 
factors include
 
mannose-fucose hemagglutinin, regulatory proteins, outer membrane porins, 
biotin and purine biosynthetic
 
genes, iron-regulated outer membrane proteins,
 
the O antigen 
of the lipopolysaccharide and accessory colonization
 
factors (Thompson et al., 2004). 
In cholera disease, fluid accumulation is greater in the upper intestine, duodenum, 
and jejunum than in the ileum. On the fourth to eighth day of illness, the number of vibrio 
decreases in the small bowel as the diarrhoea decreases and disappear. In rare cases, patients 
continue to have vibrios in the small bowel even though the diarrhoea has ceased (Thomas et 
al., 1974). 
1.12 Toxins 
The CT produced by V. cholerae during
 
the organism's colonization of its host's 
small intestine accounts
 
for the characteristic diarrhea of the disease cholera (Sanchez and 
Holmgren, 2011). It is an enterotoxin made up of five B subunits (a pentameric ring of 
11,500 daltons) and an active A subunit (Zhang et al., 1995). The A subunit contains A1 
subunit of 23,500 daltons, and an A2 of 5,500 daltons that links A1 to the 5B subunits (De 
Haan and Hirst, 2004). B subunits bind to oligosaccharide of monosialosyl ganglioside 
(GM1 ganglioside) and internalize A subunit. Binding of B subunits to GM1 induces a 
conformational change in the CT molecule (Kaper et al., 1995). This is followed by insertion 
of the A subunit into the cell via receptor-mediated endocytosis. Once inside the cell, the Gs 
alpha subunit of the heterotrimeric G protein is permanently ribosylated by it (Kaper et al., 
1995; De Haan and Hirst, 2004).  This causes an increase in adenylate cyclase activity as 
well as the level of cyclic adenosine 3‟,5‟-monophosphate (cAMP) in the cells (Kaper et al., 
1995). Elevated production of cAMP leads to secretion of H2O, Na
+
, K
+
, Cl
−
, and HCO3
−
 into 
the lumen of the small intestine; this account for the life-threatening cholera disease (Thomas 
et al., 1974; De Haan and Hirst, 2004).  
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Besides CT, there are various other toxigenic and pathogenic genes, such as zonula 
occludens toxin (zot), accessory cholera enterotoxin (ace), repeats-in-toxin (rtx), 
haemagglutinin/protease (hap), hemolysin (HlyA), outer membrane protein (ompU) and 
transmembrane transcriptional activator protein (toxR) (Fasano et al., 1991; Trucksis et al., 
1993; Kaper et al., 1995; Menzl et al., 1996; Fullner and Mekalanos, 2000; Silva et al., 
2003; Childers and Klose, 2007; Chomvarin et al., 2008).  
The ctx, zot, and ace genes comprise a V. cholerae "virulence cassette" (Trucksis et 
al., 1993), shown in Figure 1.1. Both zot and ace toxins are located immediately upstream of 
the ctx operon
 
encoding CT, and influence the pathogenesis and contribute to diarrhoea in 
cholera (Waldor and Mekalanos, 1996). Zot toxigenic gene consists of a 1.3-kb open reading 
frame, which potentially
 
encodes a 44.8-kDa polypeptide that affects the intercellular tight 
junctions and subsequently decreases intestinal tissue resistance (Fasano et al., 1991; 
Johnson et al., 1993). The third toxin of a V. cholerae virulence cassette, ace, is a 
hydrophobic protein that increases the transcellular ion transport across the epithelial layer 
(Trucksis et al., 1997). 
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Figure 1.1 Virulence cassettes within V. cholerae CTXφ locus (Ruby et al., 2005)  
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The repeats-in-toxin (RTX) exoproteins are a diverse collection
 
of proteins 
exported via type I secretion by gram-negative bacteria (Satchell, 2007).
 
RTX of V. cholerae, 
predicted to be 484,000 Da in size, is secreted
 
by a four-component type I secretion system 
(TISS) (Boardman et al., 2007). TISS is encoded by
 
rtxB, rtxD, rtxE, and tolC. The T1SS
 
consists of three components: a homodimer of an inner membrane
 
transport ATPase, a trimer 
of a transmembrane linker protein,
 
and an outer membrane porin that is either a specialized 
porin
 
or the common porin tolC (Boardman and Satchell, 2004; Lee et al., 2007).  
It has been shown that the V.
 
cholerae toxin is a novel
 
toxin distinct from the other 
RTX toxins of gram-negative bacteria and was renamed as multifunctional autoprocessing 
RTX toxin,
 
MARTXVc (Satchell, 2007). MARTXVc is not a pore-forming
 
toxin; the majority 
of RTX toxins are pore-forming toxins that lead to alteration of membrane permeability and
 
cell lysis (Seshadri et al., 2006).  
In V. cholerae,
 
the rtxA toxin genes encode the MARTXVc toxins, as shown in 
Figure 1.2. The rtxA protein that contains a glycoprotein rich repeated motif is the largest 
single polypeptide toxin in V. cholerae. It is a 4,545 amino acid in length with a predicted 
molecular mass of 484 kDa (Lin et al., 1999).  
RtxA causes the depolymerization of actin stress fibers resulting in the rapid 
rounding of cells in culture (Lin et al., 1999; Fullner and Mekalanos, 2000). This toxin-
induced depolymerization of actin, causes actin monomers to be covalently cross-linked into 
dimers, trimers,
 
and higher multimers (Fullner and Mekalanos, 2000). The integrity of the 
polarized T84 intestinal epithelial cell monolayer was found to be destroyed by it  (Fullner et 
al., 2001).  
The order of the rtx genes is CABD, where gene A encodes the toxin, genes B and 
D encode two secretory proteins, and gene C encodes the toxin activator (Lin et al., 1999). 
The organization of rtx gene clusters is shown in Figure 1.2. RtxB, rtxE and rtxD are
 
essential for V. cholerae to secrete
  
the RTX toxin (Boardman and Satchell, 2004), its activity 
depends on an activator, rtxC, and an associated ABC transporter system, rtxB and rtxD. 
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Figure 1.2 Generalized organization of rtx gene clusters (Satchell, 2007)  
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V. cholerae produces haemagglutinin/protease
 
(Hap), a soluble Zn
2+
-dependent 
metalloprotease (mucinase), encoded by hapA (Finkelstein and Hanne, 1982; Booth et al., 
1983). The extracellular Hap consists of 414 amino acids representing a
 
major protease 
secreted by V. cholerae (Hase and Finkelstein, 1991). It displays mucolytic activity that 
degrades different types of protein including fibronectin and lactoferrin (Finkelstein et al., 
1983). It also nicks the CT; when unnicked cholera enterotoxin was
 
incubated with purified 
Hap, the unnicked
 
A subunit was converted to a molecular weight consistent with
 
that of the 
A1 subunit  (Booth et al., 1984a). Hap of V. cholerae also produces CTXφ -destroying factor 
that potentially destroys the CTXφ infectivity to generate V. cholerae CTXφ lysogens, 
indirectly indicating Hap may be a factor in preventing CTXφ reinfection in natural 
environments and in the human host (Kimsey and Waldor, 1998). 
Hap perturbs the barrier function of Mardin-Darby canine kidney epithelial cell 
line I (MDCK-I) by affecting the intercellular tight junctions and the F-actin cytoskeleton 
(Wu et al., 1998). Hap digested 66-85 kDa bands of occludin, a tight junction-associated 
protein, to two predominant bands of around 50 kDa and 35 kDa. This also suggests that the 
intercellular tight junctions is affected by Hap (Wu et al., 2000). Its cytotoxic activity is 
likely to play an important role in the pathogenesis of cholera and the reactogenicity of 
attenuated vaccine strains (Robert et al., 1996; Silva et al., 2003). Its role in virulence is 
clearly not known but it is identified to have a major role in cholera pathogenesis by 
promoting mucin gel penetration, detachment and spreading of infection along the 
gastrointestinal tract (Finkelstein et al., 1992; Silva et al., 2003). Hap is thought to contribute 
to detachment rather than attachment of vibrios (Finkelstein et al., 1992) and has a positive 
effect on colonization (Robert et al., 1996). 
1.13 Diagnosis of cholera 
Cholera is confirmed through culture of a stool specimen or rectal swab from 
faeces of patients with gastroenteritis. Cary Blair media is ideal for transport (Ciufecu and 
Nacescu, 1974). Direct culturing on the selective thiosulfate–citrate–bile salts agar (TCBS) 
or alkaline peptone water (APW) enrichment prior to direct culturing on TCBS is ideal for 
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isolation and identification of V. cholerae (Lesmana et al., 1985; Sood et al., 1996). 
Diagnosis is confirmed by identification of V. cholerae in sample (Keen and Bujalski, 1992). 
Colonies identification is made by biochemical, serological tests and Polymerase Chain 
Reaction (PCR) (Grujic et al., 1991; Varela et al., 1994; Albert et al., 1997). 
1.14 Clinical manifestations of cholera 
Cholera occurs as a result of the loss of salt and water through diarrhoea (Seas and 
Gotuzzo, 1996). It begins with a sudden onset of profuse, watery diarrhoea (Lopez et al., 
2008). In most severe cases, patient experiences nausea and vomiting with extreme loss of 
water and electrolytes, mainly sodium, chloride and bicarbonate (Phillips, 1964; Seas and 
Gotuzzo, 1996). These symptoms could happen within a short time, resulting in hypovolemic 
shock and acidosis (Kaper et al., 1995; Lopez et al., 2008). Table 1.2 shows the clinical 
symptoms and signs according to the degree of dehydration. If left untreated, the disease can 
rapidly lead to serious dehydration, electrolyte imbalance, tachycardia, hypotension and 
circulatory collapse leading to death (Kaper et al., 1995; Seas and Gotuzzo, 1996; Lopez et 
al., 2008).  
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Table 1.2: Clinical Findings in Patients with Cholera according to Degree of 
Dehydration (Seas and Gotuzzo, 1996) 
 
Finding Mild Dehydration Moderate 
Dehydration 
Severe Dehydration 
Loss of fluid < 5% 5-10% > 10% 
Mentation Alert Restless Drowsy or comatose 
Radial pulse 
Rate 
Intensity 
 
Normal  
Normal 
 
Rapid  
Weak 
 
Very rapid  
Feeble or impalpable 
Respiration Normal Deep Deep and rapid 
Systolic blood 
pressure 
Normal Low Very low or 
unrecordable 
Skin elasticity Retracts rapidly Retracts slowly Retracts very slowly 
Eyes Normal Sunken Very sunken 
Voice Normal Hoarse Not audible 
Urine production Normal Scant Absent 
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1.15 Treatment of cholera 
Cholera patient can be treated effectively with oral rehydration therapy, developed 
in 1960s (Bhattacharya, 1995; Rabbani, 2000; Schultz, 2007; Nalin, 2009). According to 
WHO, 80-90% of cholera victims during an epidemic can use oral rehydration salts (WHO, 
1991). With this therapy, patients are given oral rehydration solution to make up the salt and 
water deficits and to replace ongoing losses (Bhattacharya, 1995; Rabbani, 2000). Oral 
rehydration solution is formulated based on the concentrations of salts that are lost in the 
stool in patients with cholera. The electrolyte composition of oral rehydration solution are 90 
mmol of sodium, 20 mmol of potassium, 80 mmol of chloride, 10 mmol of citrate, and 111 
mmol of glucose per litre. This electrolyte composition is recommended by the WHO and 
the United Nations Children‟s Fund for universal application as it proved to be effective and 
safe in treating all types of diarrhoea in children and adults (Rabbani, 2000).  
For effective medical care, administration of oral rehydration salts to replace lost 
fluid and electrolytes should be started right away (Carpenter, 1992; Kaper et al., 1995; 
Rabbani, 2000). If administered in a timely manner and in adequate volumes, prompt oral 
rehydration therapy nearly results in cure and reduces case–fatality rates (Carpenter, 1992; 
Bhattacharya, 1995; Seas et al., 1996; Rabbani, 2000). This may be done orally for ordinary 
case or by intravenous administration for severely dehydrated cases (Seas et al., 1996). The 
solution can not reduce the duration of illness or the volume of watery diarrhoea but limits 
dehydration and prevents acidosis (Scarpignato and Rampal, 1995; Rabbani, 2000).  
Another possible way to produce a better rehydration solution is rice-cereal-based 
to reduce diarrhoea by adding more substrate to the gut lumen without increasing osmolality 
(Molla et al., 1982; Khin Maung and Greenough, 1991). Moreover rice-based solution has 
the advantage of being more culturally acceptable and it is readily available even in rural 
homes in developing countries (Nathavitharana and Booth, 1992). Also, combined standard 
solution with nutrients, amino acids and vitamins (such as vitamin A, zinc, magnesium, 
selenium, and micronutrients) definitely will be a better oral solution (Pillai et al., 1994;  
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Rabbani, 2000). This is due to the ability of the solution to increase absorption in the small 
intestine, thus reduce the watery diarrhoea in cholera, and increase antioxidative actions. 
The use of antimicrobials is an adjunctive to rehydration therapy. Antimicrobial 
agents have been shown to reduce the volume of stool in patients and stop excretion of 
vibrios in the stool (Seas and Gotuzzo, 1996; Bhattacharya, 2003). Tetracycline, 
erythromycin, luoroquinolones, norfloxacin, lomefloxacin, ciprofloxacin and doxycycline, 
are the drugs of choice in treatment of cholera (Seas and Gotuzzo, 1996). Drugs that inhibit 
CT binding to receptors in the intestine provide an attractive strategy for managing severe 
diarrhoea in cholera. These drugs are currently not available for cholera treatment but are 
expected to be available soon (Thiagarajah and Verkman, 2005). 
1.16 Immunology of cholera 
In the small intestine, V. cholerae secretes mucinases and attach themselves to the 
villi of the cells. On the luminal surface, V. cholerae multiply and secrete cholera toxin (CT) 
(Svennerholm et al., 1994). Bacteria and secreted CT is sampled through the M cells and 
presented to immature dendritic cells. A few vibrio cells and CT may be sampled directly by 
dendritic cells. Dendritic cells process the antigens in endosomes and present the specific 
antigens on their surface with MHC class II proteins. Dendritic cells with MHC class II-
associated antigen attracts CD4+ T cells and IgA-B cells. Primed CD4+ T cells also interact 
with dendritic associated-B cells to stimulate them. Stimulated B cells leave the Peyer‟s 
patches and migrate to the mesenteric lymph nodes where they mature into IgA secreting 
plasma cells. IgA secreting plasma cells „home back‟ to the lamina propria and secrete 
antibodies. While IgA is being transported through the mucosal epithelial cells, IgA is bound 
by a secretory component and the complex is secreted into lumen as sIgA (Svennerholm, 
1994). It has been observed that although CT can itself elicit immunity, this immunity is 
short lived and lasts only six months (Fica et al., 1993). 
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1.17 Prevention of cholera 
Cholera was eliminated from the industrialized world through safe water and 
sanitation facilities and better hygiene (von Seidlein, 2007).  On the other hand in resource 
poor countries with huge population burden, lack of safe water and proper sanitation 
facilities cause sudden cholera outbreaks. This necessitated the invention of safe and 
effective cholera vaccines for prevention of disease. The advent of safe and effective oral 
vaccines against cholera has created renewed interest in the cholera-prevention efforts (Shin 
et al., 2011). Before 2002, cholera vaccines were recommended only for travellers to areas 
where the disease is endemic (Lopez et al., 2008). In 2002, WHO for the first time 
recommended the potential use of oral cholera vaccines in endemic and epidemic countries 
as an additional public health tool (WHO, 2002). Mass oral cholera vaccinations have been 
conducted in Beira, Mozambique, in Darfur, Sudan, and in Aceh, Indonesia after WHO 
experts recommended vaccinations for cholera control. These projects help experts to 
achieve more experience with vaccination under actual public health conditions (Lucas et al., 
2005).  
There are currently four licensed oral cholera vaccines, namely Dukoral™, CVD 
103HgR or Orochol™, heat-killed oral cholera vaccine by Vabiotech produced in Vietnam 
and Shanchol by Shantha Biotechnics produced in India (Table 1.3) (Lopez et al., 2008). 
Dukoral™ is produced by Crucell (formerly SBL). It contains the recombinant cholera 
B-subunit and heat or formalin killed V. cholerae organisms.  Dukoral™ is licensed for 
persons two years and older. It requires the administration of two doses of Dukoral given one 
to six weeks apart. CVD 103HgR or Orochol™ is also produced by Crucell (formerly Berna 
Biotech). Orochol is given in a single-dose and it was shown to be safe and immunogenic in 
various trials in North America (Kotloff et al., 1992), Switzerland (Cryz et al., 1992), Peru 
(Gotuzzo et al., 1993), Indonesia (Suharyono et al., 1992; Simanjuntak et al., 1993), in HIV 
seropositive individuals in Mali (Perry et al., 1998), and in challenge studies in the US 
(Tacket et al., 1999). Orochol™ has been licensed in the US and Europe for use by travellers 
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to cholera-endemic settings. Its production was halted several years ago. This is because 
there was limited market potential for Orochol™ (Lopez et al., 2008). 
Killed oral whole cell vaccine partly modeled on the Swedish vaccine has been 
developed in Vietnam by the local manufacturer Vabiotech. This vaccine contains killed 
whole cells (WC) of V. cholerae O1 and O139 without the CT B subunit. This vaccine was 
licensed in Vietnam in 1997 and it was appropriate for use in public health programs in 
developing countries for its low production cost (Thiem et al., 2006; Lopez et al., 2008). 
Vietnam is the only country in the world to have introduced the oral cholera vaccine (OCV) 
in their immunization schedule. In an open trial in Hue,  Vietnam, involving half of the 
communes of Hue that is more than 50,000 subjects older than 1 year of age, this vaccine 
was shown to have 50% long term effectiveness (Thiem et al., 2006).  
Shanchol™, an oral vaccine for cholera is manufactured by Shantha Biotechnics, 
Hyderabad, India. It consists of killed whole cells from a mixture of pathogenic strains of V. 
cholerae O1 and O139. Shanchol vaccine is recommended for children above one year old 
and adults. Two doses, one to six weeks apart is recommended. Shanchol is the first new 
vaccine to be developed and licensed with funding from the Gates Foundation (International 
Vaccine Institute, 2009). It is recommended as a supplement to conventional tools against 
cholera like safe drinking water and sanitation. It does not require dilution in a buffer (Paho, 
2010). In a study conducted in more than 65,000 persons of an endemic region of India, 
Shanchol showed 67% efficacy against cholera. Efficacy in children aged 1-5 years was 
49%, but dropped to 40% when only one dose was administered  or doses were incompletely 
ingested (Sur et al., 2009).   
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Table 1.3: Licensed oral cholera vaccines  (Lopez et al., 2008) 
 
No. Vaccine  Contents  Availability 
1. Dukoral 
(Crucell) 
1 mg of Recombinant CT B 
Plus 2.5 x 10
10
 of the following V. cholerae 
O1 organisms: 
Formalin-Killed El Tor Inaba (Phil 6973)  
Heat-Killed Classical Inaba (Cairo 48)  
Heat-Killed Classical Ogawa (Cairo 50)  
Formalin-Killed Classical Ogawa (Cairo 50) 
 
Licensed in more 
than 20 
countries, 
including the 
European Union 
2. Oral vaccine 
(Vabiotech) 
600 EU
 a 
LPS 
b
 of Formalin-Killed El Tor 
Inaba (Phil 6973) 
300 EU LPS of the following V. cholerae O1 
organisms: 
Heat-Killed Classical Inaba (Cairo 48)  
Heat-Killed Classical Ogawa (Cairo 50)  
Formalin-Killed Classical Ogawa (Cairo 50)  
600 EU LPS of V. cholerae O139 (4260B) 
 
Licensed only in 
Vietnam, new 
formulation 
undergoing 
Phase III trial in 
Kolkata, India 
3. Orochol 
(Crucell) 
Live attenuated CVD 103 HgR Licensed in some 
countries but no 
longer produced 
4. Shanchol 
(Shantha 
Biotechnics) 
 
Killed whole cells from a mixture of 
pathogenic strains of  V. cholerae O1 and 
O139 
Licensed in India 
a
EU, ELISA units 
b
LPS, lipopolysaccharide 
  
